By Lucy Parkinson, VP of Investor Research, LSN
As big pharma companies continue to look outwards for innovative new therapeutics to add to their pipelines, many entrepreneurs are thinking about how to secure a partner even at the earliest stages of product development. At RESI, our Big Pharma panelists will inform the audience on how they source and vet new external opportunities, and what you should be doing to get their support as a partner.
Moderated by Chris Haskell (VP, Head of West Coast Innovation Center – Bayer), the panelists are:
- Jessica Droge (Executive Director, Business Development – Amgen)
- Niels Emmerich (Vice President, Global Head Search and Evaluation – AbbVie)
- Kimberly Folander (Executive Director, Enabling Technologies, BD&L – Merck)
- Chris Church (Manager, Partnering and Strategy, MedImmune – AstraZeneca)
These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future. Join us at RESI to see this panel live.
Next Phase Newsletter 
Leave a Reply